Assignee
IMPACT THERAPEUTICS INC
CN·9 granted patents·1 pending application·13 citations·filing 2012–2019
Top patents by PatentIndex Score
10 records- 0180US11179392B2Solid pharmaceutical formulation of PARP inhibitors and use thereofIMPACT THERAPEUTICS INC·Filed 2016·Granted Nov 23, 2021·3 cites·7 claims
- 0280US10874670B2Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereofIMPACT THERAPEUTICS INC·Filed 2018·Granted Dec 29, 2020·2 cites·19 claims
- 0377US9926304B21-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereofIMPACT THERAPEUTICS INC·Filed 2016·Granted Mar 27, 2018·3 cites·4 claims
- 0477US9102631B21-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereofIMPACT THERAPEUTICS INC·Filed 2012·Granted Aug 11, 2015·3 cites·3 claims
- 0571US10562889B2Process for the preparation of 1-(arylmethyl)quinazoline-2,4(1H,3H)-dionesIMPACT THERAPEUTICS INC·Filed 2017·Granted Feb 18, 2020·1 cites·20 claims
- 0665US10676468B2N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereofIMPACT THERAPEUTICS INC·Filed 2013·Granted Jun 9, 2020·1 cites·17 claims
- 0763US11358955B21-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereofIMPACT THERAPEUTICS INC·Filed 2019·Granted Jun 14, 2022·0 cites·22 claims
- 0862US10703759B28,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-onesIMPACT THERAPEUTICS INC·Filed 2017·Granted Jul 7, 2020·0 cites·18 claims
- 0954US10316027B21-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereofIMPACT THERAPEUTICS INC·Filed 2018·Granted Jun 11, 2019·0 cites·3 claims
- 1047US2019255042A1Application of hedgehog pathway inhibitor in treating fibrosis diseasesIMPACT THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →